Literature DB >> 1482434

Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA.

R P Wenzel1, V T Andriole, J G Bartlett, M D Batt, W E Bullock, C G Cobbs, B Light, M A Martin, J Sanford, M A Sande.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1482434     DOI： 10.1093/clinids/14.4.973

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?

Authors:  W K Fant
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

2.  The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies.

Authors:  C Brun-Buisson
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

3.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 4.  Gram-negative bacteremia.

Authors:  S C Schimpff
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

5.  Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Authors:  J J Rusthoven
Journal:  Int J Antimicrob Agents       Date:  1994       Impact factor: 5.283
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.